Guidance bonanza: FDA, EMA, MHRA, Health Canada and PIC/S offer new advice on a range of pharma issues
From data management to evaluating new drugs for CNS metastases, a bevy of drug regulators offered up new guidance documents over the past week.
Like most guidance from drug regulators, the information contained within the documents reinforces much of what’s already known for those working in these areas. But the guidance also offers a window into what each of these agencies considers to be pertinent to this moment, in addition to all of the Covid-19-related work that they’re dealing with.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.